Organoid and Cell Therapy Platform
An organoid, a self-organizing organ-like tissue developed from stem cells, can exhibit a miniaturized three-dimensional (3D) structure and part of the physiological functions of the original organ. Clinical trials have been performed using patient-derived organoids (PDO) as a tool for personalized medical decisions to predict patients’ responses to therapeutic regimens. In the field of regenerative medicine, organoids hold promise for the generation of future advanced therapeutic medicinal products for organ repair.
The organoid platform relies on the organoid research center in the State Key Laboratory of Genetic Engineering of Fudan University to develop organoid technology for precision medicine and transplantation use. We will focus on fully automated high-throughput workflows for improved scalability, reproducibility of organoid production and novel organoid-based drug screening platforms.
The platform focuses on two main areas:
1) Patient-Derived Organoids in Precision Medicine: It consists of three departments: living organoid biobank , organoid high-throughput drug screening department and organoid molecular pathology department. Through the collaboration with the hospital and research center, Patient-derived organoids will be used to investigate the biology of various types of diseases and test the efficacy of drug candidates.
2)Regenerative Medicine: It’s committed to developing frontier technologies of organoid regenerative medicine and its application in intestine, liver, pancreas, lung and other organ repair by building two functional modules: organoid live cell dynamic imaging platform and organoid single cell system .
Cell therapy represents the most recent phase of the biotechnology revolution in medicine. CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma. Particularly, this treatment offers unique clinical and therapeutic advantages over conventional small molecules. Cell therapies have emerged as a promising therapeutic modality with the potential to treat a diverse array of diseases, such as solid tumors, cardiovascular and nervous system diseases.
Cell therapy platform relies on the Biotherapy Center of Zhongshan Hospital Affiliated to Fudan University to develop cell therapy technology for clinical applications. The aims of cell therapy platform consist of: 1）equipping automated cell processing system that enables scalable GMP-compliant manufacturing of cell therapy products; 2)building comprehensive tumor-specific antigen therapeutic industrial chain which includes bioinformatics platform, T cell biology platform and tumor/immune cell phenome database;3) using the integrated GMP facilities to conduct IIT and IND clinical trials, and bring cell therapy technology to market faster.
Autologous and allogeneic cell therapies
Therapeutic potential of organoids